1. Inicio
  2. Publicaciones
  3. A New Approach for Achieving Earlier and More Accurate Diagnosis of Connective Tissue Disease-Related Interstitial Lung Disease: TGFB and PDGFA as Novel Promising Biomarkers.

A New Approach for Achieving Earlier and More Accurate Diagnosis of Connective Tissue Disease-Related Interstitial Lung Disease: TGFB and PDGFA as Novel Promising Biomarkers.

Fecha de publicación: Fecha Ahead of Print:

Autores de IDIVAL

Autores ajenos al IDIVAL

  • Sebastián Mora-Gil M
  • Izquierdo-Cuervo S
  • Aguirre Portilla C

Unidades

Abstract

An early and accurate diagnosis of connective tissue diseases-related interstitial lung disease (CTD-ILD) is crucial for delaying lung fibrosis, but its unknown etiology and the limitations of clinical tools make it challenging for clinicians. PDGF and TGFB are the main profibrotic genes. We evaluated PDGFA, TGFB1, TGFB2, and TGFB3 role in the diagnosis of ILD associated with rheumatoid arthritis (RA), systemic sclerosis (SSc), and inflammatory myopathies (IM). Blood was collected from 289 patients:33 RA-ILD, 31 SSc-ILD, 29 IM-ILD; and 22 RA-nonILD, 18 SSc-nonILD, 8 IM-nonILD; and 148 idiopathic pulmonary fibrosis (IPF). The relative expression was quantified by qPCR. Lower PDGFA, TGFB1, and TGFB2 expression differentiated RA-ILD from RA-nonILD patients, acting as ILD early diagnostic biomarkers in RA with cut-offs of <0.01153, <0.3185, and <0.001410, respectively. SSc-ILD patients revealed decreased TGFB2 expression compared to SSc-nonILD patients, with a cut-off of <0.0018 identifying ILD in SSc. PDGFA and TGFB2 expression discriminated IM-ILD from IPF acting as accurate diagnostic biomarkers with cut-offs of >0.0166 and >0.001547, respectively. PDGFA and TGFB2, as well as TGFB2 and TGFB3 expression were associated with RA-ILD and SSc-ILD prognosis, respectively. PDGFA and TGFB are promising blood biomarkers with clinical value for the early and accurate CTD-ILD diagnosis.

Datos de la publicación

ISSN/ISSNe:
1661-6596, 1422-0067

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES  MDPI AG

Tipo:
Article
Páginas:
-
PubMed:
41226758

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • biomarkers; connective tissue diseases; inflammatory myopathies; interstitial lung disease; profibrotic genes; pulmonary fibrosis; rheumatoid arthritis; systemic sclerosis

Campos de Estudio

Financiación

Boehringer Ingelheim España, S.A. (CSI24/72)
FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (INNVAL24/10)
FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA (NVAL23/02)
INSTITUTO DE SALUD CARLOS III. (CPII21/00004)
INSTITUTO DE SALUD CARLOS III. (FI22/00020)

Proyectos asociados

Contratos Miguel Servet Tipo II

Investigador Principal: Raquel López Mejías

CPII21/00004 . INSTITUTO DE SALUD CARLOS III. . 2022

Contratos predoctorales de formación en investigación en salud (PFIS)

Investigador Principal: Raquel López Mejías

FI22/00020 . INSTITUTO DE SALUD CARLOS III. . 2023

TGF-β1 a nivel génico y proteico: nuevo abordaje al desafío del diagnóstico precoz y preciso de la enfermedad pulmonar intersticial asociada a enfermedades autoinmunes

Investigador Principal: Verónica Pulito Cueto

NVAL23/02 . FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA . 2023

Contrato para la realización del proyecto: "TGF-β1 and PDGFA at the gene and protein level: a new approach to the challenge of early and accurate diagnosis of interstitial lung disease associated with autoimmune diseases".

Investigador Principal: Verónica Pulito Cueto

CSI24/72 . Boehringer Ingelheim España, S.A. . 2024

Abordaje biológico del infradiagnóstico de la miocardiopatía asociada a la esclerosis sistémica: primer estudio de Hsp90 e ICAM-1 en monocitos circulantes como nuevos biomarcadores

Investigador Principal: Verónica Pulito Cueto

INNVAL24/10 . FUNDACION INSTITUTO DE INVESTIGACION MARQUES DE VALDECILLA . 2024

Compartir